

Pancreatic factor promotes remyelination in the central nervous system after injury

August 25 2017




Figure 1. Remyelination is promoted by peripheral FGF21. Credit: Osaka University

Brain functions are maintained by the neural network. Neural network is

formed by the connection between the neurite, and this connection is supported by the wrapping of myelin. Demyelination is detected in the patients of several diseases, such as multiple sclerosis, and is associated with neurological dysfunctions. A new study in the *Journal of Clinical Investigation* by scientists at Osaka University shows that fibroblast growth factor (FGF) 21 promotes remyelination in mice and may be a promising key molecule for treating demyelinating diseases.

In normal development, oligodendrocyte precursor cells (OPCs) differentiate into oligodendrocytes, which are required for myelination. OPCs will proliferate around the [lesions](#) of demyelination after injury and contribute to spontaneous [remyelination](#), but the molecular mechanism of OPCs proliferation is not fully clarified. Osaka University Associate Professor Rieko Muramatsu focused on the blood leakage around demyelinating lesion.

"Factors in the blood cannot reach the normal brain because central nervous system has [blood-brain barrier](#). In demyelination diseases like [multiple sclerosis](#), the blood-brain barrier around the lesion is disrupted," she said.

Muramatsu suspected that with the breach, factors from peripheral organs secreted into the blood could now reach the brain.

To test her hypothesis, "We disrupted the vascular barrier and myelin structures in mice by injecting Lysophosphatidylcholine (LPC). We looked for circulating factors that promote OPCs proliferation and found FGF21 as a candidate," she said.




Figure 2. FGF21 knockout mice (FGF21 KO) show inhibition of remyelination and functional recovery after demyelination. Credit: Osaka University

Mice treated with LPC showed high levels of FGF21 around demyelinated lesions leading to remyelination. This was not the case in [mutant mice](#) that could not express FGF21. Other mice that received direct administration of FGF21 to demyelinated lesions caused by LPC injection also showed increased remyelination and better recovery of neurological function.

In addition, the researchers found OPCs expressed higher levels of b-klotho, co-receptor for FGF21, following LPC injection. Without this expression, FGF21 could not promote remyelination.

"FGF21 is known to regulates metabolism, but its effects on OPC proliferation were unexpected," said Muramatsu.




Figure 3. FGF21 treatment promotes human OPC proliferation. Credit: Osaka University

The results suggest that FGF21 has therapeutic potential for [demyelinating diseases](#). FGF21 analogs are already being used for clinical studies on diabetes, which means its development for remyelination could go faster than had it been an untested compound.

"There are many drugs that inhibit demyelination, but none that promote remyelination. FGF21 is a new candidate that deserves more testing. The most important finding is that we show the peripheral milieu promotes central nervous system remyelination."

More information: Mariko Kuroda et al. Peripherally derived FGF21 promotes remyelination in the central nervous system, *Journal of Clinical Investigation* (2017). [DOI: 10.1172/JCI94337](https://doi.org/10.1172/JCI94337)

Provided by Osaka University

Citation: Pancreatic factor promotes remyelination in the central nervous system after injury (2017, August 25) retrieved 12 January 2023 from <https://medicalxpress.com/news/2017-08-pancreatic-factor-remyelination-central-nervous.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--